Description: The FlashForward Consortium's mission is to continue research and build an evidence-based introduction of Flash therapy using the ProBeam platform.
Flash therapy could be one of the most significant advancements in cancer treatment in decades.
Flash therapy is an experimental treatment modality delivering radiotherapy at ultra-high dose rates to treatment volumes in typically <1 second. Compared to conventional therapy, preclinical studies in mice have shown equivalent or better tumor control, reduced normal tissue toxicity, and immunological advantages.
Varian’s FlashForward™ Consortium is formed from institutions around the world to establish preclinical study designs, develop technical solutions, and share research protocols to help advance the science and clinical translation of Flash therapy.